Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $2.4 million.

  • Cardiff Oncology's Accounts Payables fell 4742.62% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 4742.62%. This contributed to the annual value of $4.8 million for FY2024, which is 14521.87% up from last year.
  • As of Q3 2025, Cardiff Oncology's Accounts Payables stood at $2.4 million, which was down 4742.62% from $6.0 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Accounts Payables peaked at $6.0 million during Q2 2025, and registered a low of $396000.0 during Q3 2021.
  • For the 5-year period, Cardiff Oncology's Accounts Payables averaged around $2.7 million, with its median value being $2.2 million (2023).
  • Per our database at Business Quant, Cardiff Oncology's Accounts Payables plummeted by 5300.86% in 2021 and then skyrocketed by 25984.85% in 2022.
  • Cardiff Oncology's Accounts Payables (Quarter) stood at $1.4 million in 2021, then soared by 35.93% to $2.0 million in 2022, then increased by 0.51% to $2.0 million in 2023, then surged by 145.22% to $4.8 million in 2024, then tumbled by 49.37% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $6.0 million for Q2 2025, and $3.6 million during Q1 2025.